Buoyed by soaring revenues from its monkeypox vaccine, Bavarian Nordic A/S is using some of its cash pile to buy a portfolio of travel vaccines from US firm Emergent BioSolutions, Inc. in a deal worth up to $380m.
The Danish firm is acquiring two marketed travel vaccines - Vivotif for the prevention of typhoid fever and Vaxchora against cholera - as well as a Phase III vaccine candidate for the prevention of Chikungunya virus
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?